Safety and immunogenicity of REMUNE™ in HIV-infected Thai subjects
1998; Elsevier BV; Volume: 16; Issue: 2-3 Linguagem: Inglês
10.1016/s0264-410x(97)88327-2
ISSN1873-2518
AutoresA Limsuwan, Vina Churdboonchart, Ronald B. Moss, Worachart Sirawaraporn, Reungpung Sutthent, Buranaj Smutharaks, David V. Glidden, Richard Trauger, Georgia Theofan, Dennis J. Carlo,
Tópico(s)HIV/AIDS drug development and treatment
ResumoThe safety and immunogenicity of REMUNE, an HIV-specific immune based therapy for HIV infection, was evaluated in a cohort of 30 HIV infected subjects in Thailand. This therapy utilizes a gp120 depleted inactivated virus (HZ321), which exhibits a high degree of conservation with the core antigens of both type B' and E strains of HIV, the predominant Thailand isolates. The treatment was well tolerated, with no serious adverse events reported over the course of the 4-month trial. Treatment in which four doses were administered with REMUNE appeared to boost HIV-specific immune responses, with approximately 75% of the treated subjects demonstrating an increase in either the repertoire or the intensity of the serological response to HIV as measured by Western blot. CD4%, viral load, and weight remained stable over the course of the 4-month study relative to baseline values. Viral subtyping of this cohort revealed a predominance of type 'E'. These data suggest that REMUNE is safe and immunogenic in seropositive Thai subjects and supports further study of the therapeutic potential of REMUNE to treat HIV-1 infection.
Referência(s)